drugset / Trial / NCT05314101
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2023-02-28
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | TAS-102 | Small molecule | 35 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |